3,4-Diaminopyridine

From Wikipedia, the free encyclopedia

This article or section is in need of attention from an expert on the subject. WikiProject Medicine or the Medicine Portal may be able to help recruit one. If a more appropriate WikiProject or portal exists, please adjust this template accordingly.

3,4-Diaminopyridine
Systematic (IUPAC) name
3,4-Diaminopyridine
Identifiers
CAS number	54-96-6
ATC code	?
PubChem	?
Chemical data
Formula	C5H7N3
Mol. mass	109.13
Pharmacokinetic data
Bioavailability	30% [1],[2]
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	Phase III
Routes	Oral

3,4-Diaminopyridine is an experimental drug used in the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca²⁺ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca²⁺ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate.

It has also been proposed for use in multiple sclerosis.^[3]

[edit] See also

• 4-Aminopyridine

[edit] References

1. ^ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve 24: 1236–1238. doi:10.1002/mus.1139. 
2. ^ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.". Acta Neurol Scand 88: 136–140. 
3. ^ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID 16472864.